Method of administration: Oral use.
Dosage regimen: As far as possible the treatment must be tailored to the needs of the individual.
Depending on the clinical picture in each case, the basic dose must be introduced gradually.
Unless otherwise prescribed, the following dosage guidelines are recommended for adults: For coronary heart disease: Chronic stable angina pectoris (angina of effort): 1 Adalat LA 30 mg tablet once daily (1 x 30 mg/day).
For hypertension: 1 Adalat LA 30 mg tablet once daily (1 x 30 mg/day).
In general therapy should be initiated with 30 mg once daily.
Depending on the severity of the disease and the patient's response the dose can be increased in stages up to 120 mg once daily.
Coadministration with CYP 3A4 inhibitors or CYP 3A4 inducers may result in the recommendation to adapt the nifedipine dose or not to use nifedipine at all (see Interactions).
Duration of Treatment: The attending doctor will determine the duration of use.
Administration: The tablets must not be chewed or broken up.
As a rule Adalat LA tablets are swallowed whole with a little liquid, irrespective of meal times. Grapefruit juice is to be avoided (see Interactions).
Additional information on special populations: Pediatric patients: The safety and efficacy of Adalat LA in children below 18 years has not been established.
Geriatric patients: Based on pharmacokinetic data for Adalat LA no dose adaptation in elderly people above 65 years is necessary.
Patients with hepatic impairment: In patients with mild, moderate or severe impaired liver function, careful monitoring and a dose reduction may be necessary. The pharmacokinetics of nifedipine has not been investigated in patients with severe hepatic impairment (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Patients with renal impairment: Based on pharmacokinetic data no dosage adjustment is required in patients with renal impairment (see Pharmacology: Pharmacokinetics under Actions).
The tablets must not be chewed or broken up.